credit-freepik
Study by Mass General Brigham explores a link between diabetes drugs and reduced kidney stone risk.
credit-freepik
Kidney stones on the rise worldwide, especially in individuals with Type 2 diabetes.
credit-freepik
SGLT2 inhibitors show promise in lowering the likelihood of kidney stone development
.
credit-freepik
Data from 716,406 adults with Type 2 diabetes analyzed in a comprehensive study publi
shed in JAMA Internal Medicine.
credit-freepik
Individuals starting SGLT2 inhibitors have a 30% lower risk of kidney stones compared to GLP1 agonists.
credit-freepik
Consistent findings across various demographics highlight potential universal applicability.
credit-freepik
Brigham and Women's Hospital and Massachusetts General Hospital researchers jointly conduct the groundbreaking investigation.
credit-freepik
Dr. Julie Paik underscores the study's potential impact on clinical decision-making for diabetic patients at risk of kidney s
tones.
credit-freepik
Consistency in outcomes offers hope for diverse patient groups, irrespective of sex, race, chronic kidney disease history, or obesi
ty.
credit-freepik
Research unveils key link between SGLT2 inhibitors and renal health, heralding transformative potential for global diabetic patient care